A comprehensive review of protein kinase inhibitors for cancer therapy
R Kannaiyan, D Mahadevan - Expert review of anticancer therapy, 2018 - Taylor & Francis
Introduction: Protein kinases are involved in various cellular functions. About 2% of the
human genome encodes for protein kinases. Dysregulation of protein kinases is implicated …
human genome encodes for protein kinases. Dysregulation of protein kinases is implicated …
Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials
M Schwaederle, M Zhao, JJ Lee… - Journal of clinical …, 2015 - ascopubs.org
Purpose The impact of a personalized cancer treatment strategy (ie, matching patients with
drugs based on specific biomarkers) is still a matter of debate. Methods We reviewed phase …
drugs based on specific biomarkers) is still a matter of debate. Methods We reviewed phase …
LLPS of SQSTM1/p62 and NBR1 as outcomes of lysosomal stress response limits cancer cell metastasis
T Noguchi, Y Sekiguchi, T Shimada… - Proceedings of the …, 2023 - National Acad Sciences
Liquid droplet has emerged as a flexible intracellular compartment that modulates various
cellular processes. Here, we uncover an antimetastatic mechanism governed by the liquid …
cellular processes. Here, we uncover an antimetastatic mechanism governed by the liquid …
Targeted engineering of medicinal chemistry for cancer therapy: recent advances and perspectives
W Chen, Z Sun, L Lu - Angewandte Chemie International …, 2021 - Wiley Online Library
Severe side effects and poor therapeutic efficacy are the main drawbacks of current
anticancer drugs. These problems can be mitigated by targeting, but the targeting efficacy of …
anticancer drugs. These problems can be mitigated by targeting, but the targeting efficacy of …
[HTML][HTML] Gefitinib initiates sterile inflammation by promoting IL-1β and HMGB1 release via two distinct mechanisms
T Noguchi, Y Sekiguchi, Y Kudoh, R Naganuma… - Cell Death & …, 2021 - nature.com
Anticancer drug gefitinib causes inflammation-based side effects, such as interstitial
pneumonitis. However, its mechanisms remain unknown. Here, we provide evidence that …
pneumonitis. However, its mechanisms remain unknown. Here, we provide evidence that …
Drug encapsulated polymeric microspheres for intracranial tumor therapy: a review of the literature
JA Floyd, A Galperin, BD Ratner - Advanced drug delivery reviews, 2015 - Elsevier
Despite intensive surgical excision, radiation therapy, and chemotherapy, the current life
expectancy for patients diagnosed with glioblastoma multiforme is only 12 to 15 months …
expectancy for patients diagnosed with glioblastoma multiforme is only 12 to 15 months …
Measuring Drug Response with Single-Cell Growth Rate Quantification
Intratumoral heterogeneity is a substantial cause of drug resistance development during
chemotherapy or other drug treatments for cancer. Therefore, monitoring and measuring cell …
chemotherapy or other drug treatments for cancer. Therefore, monitoring and measuring cell …
RETRACTED ARTICLE: The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC
X Li, X Zhang, C Yang, S Cui, Q Shen, S Xu - Cell Cycle, 2018 - Taylor & Francis
Statement of Retraction We, the Editors and Publisher of the journal Cell Cycle, have
retracted the following article: Xuehao Li, Xin Zhang, Chunlu Yang, Sui Cui, Qiming Shen …
retracted the following article: Xuehao Li, Xin Zhang, Chunlu Yang, Sui Cui, Qiming Shen …
Development of novel S PC-3 gefitinib lipid nanoparticles for effective drug delivery in breast cancer. Tissue distribution studies and cell cytotoxicity analysis
S Nayek, NM Raghavendra, BS Kumar - Journal of drug delivery science …, 2021 - Elsevier
Objective The present work was aimed to develop gefitinib solid lipid nanoparticles (GFT-
SLN) using novel lipids (Lipoid S PC-3) and to analyse its cell cytotoxicity and tissue …
SLN) using novel lipids (Lipoid S PC-3) and to analyse its cell cytotoxicity and tissue …
In vitro anti-cancer effects of gefitinib via EGF receptor-targeted delivery on triple-negative breast cancer cells
JW Ahn, YJ Song, K Park - Macromolecular Research, 2023 - Springer
Targeting the epidermal growth factor receptor (EGFR) is an alternative therapeutic strategy
for the treatment of triple-negative breast cancer (TNBC). Here, we designed EGFR-targeting …
for the treatment of triple-negative breast cancer (TNBC). Here, we designed EGFR-targeting …